

	Dapagliflozin		Placebo			Hazard Ratio (95% CI)	P Value for Interaction	Absolute Risk Difference, % (95% CI)	P Value for Interaction
	<i>n/N</i>		<i>Events/100 patient-years</i>						
Primary outcome: eGFR decline ≥50%, ESKD, or kidney or CV death									
Overall	197/2152	312/2152	4.6	7.5		0.61 (0.51, 0.72)		5.3 (3.4, 7.3)	
Normal glucose	28/368	41/370	4.1	6.1		0.62 (0.39, 1.01)	0.19	3.5 (-0.7, 7.7)	0.42
Pre-diabetes	17/329	42/331	2.6	6.5		0.37 (0.21, 0.66)		7.5 (3.2, 11.8)	
Diabetes	152/1455	229/1451	5.2	8.0		0.64 (0.52, 0.79)		5.3 (2.9, 7.8)	
ESKD									
Overall	109/2152	161/2152	2.5	3.8		0.64 (0.50, 0.82)		2.4 (1.0, 3.9)	
Normal glucose	19/368	32/370	2.8	4.7		0.54 (0.30, 0.95)	0.72	3.5 (-0.2, 7.1)	0.81
Pre-diabetes	13/329	20/331	2.0	3.1		0.57 (0.28, 1.15)		2.1 (-1.2, 5.4)	
Diabetes	77/1455	109/1451	2.6	3.7		0.69 (0.51, 0.92)		2.2 (0.4, 4.0)	
eGFR decline ≥50%									
Overall	112/2152	201/2152	2.6	4.8		0.53 (0.42, 0.67)		4.1 (2.6, 5.7)	
Normal glucose	20/368	31/370	2.9	4.6		0.58 (0.33, 1.01)	0.60	2.9 (-0.7, 6.6)	0.71
Pre-diabetes	13/329	30/331	2.0	4.6		0.39 (0.20, 0.74)		5.1 (1.4, 8.9)	
Diabetes	79/1455	140/1451	2.7	4.9		0.55 (0.42, 0.72)		4.2 (2.3, 6.1)	